Literature DB >> 23450025

Diffuse pigmented villonodular synovitis (diffuse-type giant cell tumour) of the foot and ankle.

J D Stevenson1, A Jaiswal, J J Gregory, D C Mangham, G Cribb, P Cool.   

Abstract

Pigmented villonodular synovitis (PVNS) is a rare benign disease of the synovium of joints and tendon sheaths, which may be locally aggressive. We present 18 patients with diffuse-type PVNS of the foot and ankle followed for a mean of 5.1 years (2 to 11.8). There were seven men and 11 women, with a mean age of 42 years (18 to 73). A total of 13 patients underwent open or arthroscopic synovectomy, without post-operative radiotherapy. One had surgery at the referring unit before presentation with residual tibiotalar PVNS. The four patients who were managed non-operatively remain symptomatically controlled and under clinical and radiological surveillance. At final follow-up the mean Musculoskeletal Tumour Society score was 93.8% (95% confidence interval (CI) 85 to 100), the mean Toronto Extremity Salvage Score was 92 (95% CI 82 to 100) and the mean American Academy of Orthopaedic Surgeons foot and ankle score was 89 (95% CI 79 to 100). The lesion in the patient with residual PVNS resolved radiologically without further intervention six years after surgery. Targeted synovectomy without adjuvant radiotherapy can result in excellent outcomes, without recurrence. Asymptomatic patients can be successfully managed non-operatively. This is the first series to report clinical outcome scores for patients with diffuse-type PVNS of the foot and ankle.

Entities:  

Mesh:

Year:  2013        PMID: 23450025     DOI: 10.1302/0301-620X.95B3.30192

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  8 in total

1.  Patient-Reported Outcome Measures in Sports Medicine: A Concise Resource for Clinicians and Researchers.

Authors:  Kenneth C Lam; Ashley N Marshall; Alison R Snyder Valier
Journal:  J Athl Train       Date:  2020-02-07       Impact factor: 2.860

2.  Diffuse-type giant cell tumor of the tendon sheath in the temporal region incidentally diagnosed due to a temporal tumor: A report of two cases and review of the literature.

Authors:  Jia Ruo Qin; Long Jin; Kong Liang Li; Shan Shan Zhang; Jie Kong; Hong Yu Yang
Journal:  Oncol Lett       Date:  2015-05-28       Impact factor: 2.967

3.  Results and recurrence of pigmented villonodular synovitis of the ankle: does diffuse PVNS with extra-articular extension tend to recur more often?

Authors:  QinWei Guo; WeiLi Shi; Chen Jiao; Xing Xie; Dong Jiang; YueLin Hu
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-04-07       Impact factor: 4.342

4.  Pigmented villonodular synovitis on lumbar spine : a case report and literature review.

Authors:  Sung Woon Oh; Min Ho Lee; Whan Eoh
Journal:  J Korean Neurosurg Soc       Date:  2014-09-30

5.  Surgical treatment for diffused-type giant cell tumor (pigmented villonodular synovitis) about the ankle joint.

Authors:  Xingchen Li; Yang Xu; Yuan Zhu; Xiangyang Xu
Journal:  BMC Musculoskelet Disord       Date:  2017-11-14       Impact factor: 2.362

6.  [Imminent fracture of the tibia due to an osteolytic lesion caused by an intraosseous tenosynovial giant cell tumor : An unusual clinico-histopathological constellation].

Authors:  Sebastian Klingebiel; Sebastian Mühl; Georg Gosheger; Wolfgang Hartmann; Kristian Nikolaus Schneider; Tymoteusz Borys Budny; Carolin Rickert; Dominik Schorn; Niklas Deventer; Timo Lübben
Journal:  Orthopade       Date:  2021-03       Impact factor: 1.087

7.  Treatment, recurrence rates and follow-up of Tenosynovial Giant Cell Tumor (TGCT) of the foot and ankle-A systematic review and meta-analysis.

Authors:  M Siegel; L Bode; N Südkamp; J Kühle; J Zwingmann; H Schmal; G W Herget
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

8.  Unusual manifestations of diffuse-type tenosynovial giant cell tumor in two patients: importance of radiologic-pathologic correlation.

Authors:  Ayca Dundar; Jason R Young; Doris E Wenger; Carrie Y Inwards; Stephen M Broski
Journal:  Skeletal Radiol       Date:  2019-10-28       Impact factor: 2.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.